Top 50 Biotech Startup Investors in Germany (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
49 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $1.1M–$33M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
19 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
Bayern Kapital
VC Fund
|
18 | Germany, United States, Finland | Seed, Series A | Software, Health Care, Information Technology | $1.1M–$32M |
|
MIG Capital
VC Fund
|
16 | Germany, France, Austria | Series A, Series B | Biotechnology, Health Care, Therapeutics | $1.6M–$54M |
|
KfW
VC Fund
|
16 | Germany, India, United Kingdom | Series A, Series B | Biotechnology, Software, Health Care | $2.2M–$17M |
|
NRW.BANK
VC Fund
|
16 | Germany, United States, France | Seed, Series A, Series B | Information Technology, Software, Biotechnology | $219k–$71M |
|
Wellington Partners
VC Fund
|
9 | Germany, United States, United Kingdom | Series A, Series B | Health Care, Biotechnology, Medical | $3.1M–$55M |
|
BioMedPartners
VC Fund
|
9 | Switzerland, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.9M–$83M |
|
b.value AG
VC Fund
|
9 | Germany, Poland | Seed, Series A | Biotechnology, Manufacturing, Chemical | $478k–$39M |
|
TGFS - Technologiegründerfonds Sachsen
VC Fund
|
9 | Germany, United States | Seed, Series A | Software, Information Technology, Manufacturing | $932k–$15M |
|
IFB Innovationsstarter
VC Fund
|
8 | Germany, United States | Seed, Grant | Software, SaaS, Artificial Intelligence | $80k–$3M |
|
Techno Venture Management
VC Fund
|
7 | United States, Germany, United Kingdom | Series B, Series A | Biotechnology, Health Care, Pharmaceutical | $4.7M–$44M |
|
eCAPITAL ENTREPRENEURIAL PARTNERS
VC Fund
|
6 | Germany, United States, Italy | Series A, Series B | Information Technology, Software, Manufacturing | $2.7M–$35M |
|
bmp Ventures
VC Fund
|
6 | Germany, United States, Austria | Seed, Series A | Software, Information Technology, Manufacturing | $30k–$5.9M |
|
bm-t beteiligungsmanagement thuringen
VC Fund
|
6 | Germany, United States | Seed, Series A | Software, Health Care, Information Technology | $461k–$9.4M |
|
IBB Ventures
VC Fund
|
6 | Germany, United States, United Kingdom | Seed, Series A | Software, Health Care, SaaS | $1M–$10M |
|
coparion
VC Fund
|
6 | Germany, Switzerland, United States | Series A, Seed, Series B | Software, SaaS, FinTech | |
|
EQT Ventures
VC Fund
|
6 | Sweden, Germany, United States | Series A, Seed, Series B | Software, Artificial Intelligence, Information Technology | $3.3M–$100M |
|
Forbion Capital Partners
VC Fund
|
6 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$176M |
|
EMBL Ventures
VC Fund
|
5 | Germany, Austria, Ireland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.9M–$70M |
|
BayBG Venture Capital
VC Fund
|
5 | Germany, Italy, United States | Series A, Series B | Software, Information Technology, Health Care | $428k–$21M |
|
Brandenburg Kapital
VC Fund
|
5 | Germany, United Kingdom | Seed, Series A | Software, Information Technology, Health Care | $823k–$13M |
|
Seed Fonds Aachen
VC Fund
|
4 | Germany | Seed, Series A | Biotechnology, Medical, Health Care | $2.2M–$6M |
|
EIC Fund
VC Fund
|
4 | Germany, The Netherlands, Austria | Pre-Seed, Seed | Biotechnology, Health Care, Information Technology | |
|
Andera Partners
VC Fund
|
4 | France, United States, Germany | Series B, Private Equity | Biotechnology, Health Care, Medical | $14M–$247M |
|
German Federal Ministry of Research, Technology and Space
VC Fund
|
4 | Germany, United States, Canada | Grant, Seed, Series B | Biotechnology, Medical, Health Care | $294k–$11M |
|
LSP BioVentures
VC Fund
|
4 | United States, Germany, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $5.3M–$176M |
|
BlueYard Capital
VC Fund
|
4 | United States, Germany, United Kingdom | Seed, Series A, Pre-Seed | Software, Biotechnology, Internet | $200k–$47M |
|
better ventures
VC Fund
|
4 | Germany, Switzerland | Pre-Seed, Seed, Series A | Software, Food and Beverage, E-Commerce | $1.1M–$6.9M |
|
CPT Capital
VC Fund
|
4 | United States, Israel, United Kingdom | Seed, Series A, Series B | Food and Beverage, Biotechnology, Food Processing | $1.3M–$226M |
|
Creathor Ventures
VC Fund
|
4 | Germany, Switzerland, United States | Series A, Series B | Software, Health Care, Biotechnology | $2M–$20M |
|
Grazia Equity
VC Fund
|
4 | Germany, United States, Switzerland | Series A, Series B, Seed | Internet, E-Commerce, Biotechnology | $1.1M–$59M |
|
Amino Collective
VC Fund
|
4 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $125k–$37M |
|
DvH Ventures
VC Fund
|
4 | Germany, Austria, United Kingdom | Seed, Series A | Health Care, Software, Financial Services | $1.2M–$31M |
|
S-Venture Capital Dortmund
VC Fund
|
4 | Germany | Series B, Series A | Biotechnology, Guides, Genetics | $3.6M–$9M |
|
Think.Health
VC Fund
|
3 | Germany, United States, France | Seed, Series A, Series B | Health Care, Biotechnology, Medical Device | $1.1M–$28M |
|
ERP Startfonds
VC Fund
|
3 | Germany, United States | Series B, Series A | Biotechnology, Pharmaceutical, Apps | |
|
Delivery Hero Ventures
VC Fund
|
3 | Singapore, Egypt, Brazil | Series A, Seed, Series B | E-Commerce, Information Technology, Food Delivery | |
|
TVM Capital
VC Fund
|
3 | United States, Germany, United Kingdom | Series B, Series C | Biotechnology, Health Care, Pharmaceutical | $7.5M–$55M |
|
Elevat3 Capital
VC Fund
|
3 | Germany, United Kingdom | Series A, Series B, Post-IPO Equity | FinTech, Apps, Social | $45M–$157M |
|
Lowercarbon Capital
VC Fund
|
3 | United States, United Kingdom, France | Seed, Series A, Series B | Renewable Energy, Energy, Biotechnology | $3.7M–$150M |
|
Global Asset Fund
VC Fund
|
3 | Germany | Series A, Series B | Medical, Therapeutics, Biotechnology | $1M–$2.9M |
|
Agronomics
VC Fund
|
3 | United States, Finland, Germany | Series A, Seed, Series B | Biotechnology, Food and Beverage, Food Processing | $894k–$55M |
|
Gruenderfonds Ruhr
VC Fund
|
3 | Germany | Series A, Seed, Series B | Health Care, Biotechnology, Renewable Energy | $4.9M–$95M |
|
Kurma Partners
VC Fund
|
3 | France, Switzerland, Spain | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $2.3M–$95M |
|
Lima Ventures
VC Fund
|
3 | Turkey, United Kingdom, Estonia | Seed, Pre-Seed | Artificial Intelligence, Software, FinTech | |
|
TechVision Fund
VC Fund
|
3 | Germany, Spain | Seed, Series A, Pre-Seed | Software, Health Care, Manufacturing | |
|
Ananda Impact Ventures
VC Fund
|
3 | Germany, United Kingdom, Finland | Seed, Series A | Health Care, Software, Information Technology | |
|
SFO
VC Fund
|
3 | Germany | Seed, Pre-Seed, Series A | Food and Beverage, B2C, Pet | |
|
Cascara Ventures
VC Fund
|
3 | Germany, Finland, The Netherlands | Series A, Seed, Series B | Medical, Health Care, Biotechnology | |
| Access all 874 investors in Germany Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 587
- Round size: Seed $1.1M–$7.3M; Series A $3.5M–$33M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- Selfapy — Selfapy offers a therapy support tool that helps recognize negative patterns of thought and train new behavior. Selfapy is your guided, self-help online course against depression with a personal psychologist as a companion.
- Verovaccines — VEROVACCiNES discovers and develops innovative vaccine solutions, to protect animals against infectious diseases. Key is a novel, broadly applicable, yeast-based technology to generate subunit marker vaccines. This technology has been validated by demonstrating protection of several target animal species against different viral diseases(proof-of-concept).VEROVACCiNES GmbH is a spin-off company of the Martin Luther University Halle-Wittenberg, Germany in 2017. The company exclusively took over IP, brand, team, products and know-how from the former BMBF GO-Bio-funded VEROVACCiNES project at Halle University. VEROVACCiNES GmbH is eligible for follow-up phase 2 funding from the same BMBF GO-Bio program. They cooperate closely with veterinary pharmaceutical companies, universities and research institutes, and they are eager to initiate new collaborations.
- OMEICOS Therapeutics — OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 101
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
- ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Bayern Kapital (founded at the end of 1995) is a wholly owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank). Bayern Kapital’s objective is to finance research and development as well as the market launch of new products, product diversifications, and expansion of the market share.The requesting company has to be located inBavaria. Industries are e. g. IT/software, life sciences, new materials, micro-systems and environmental technologies.Bayern Kapital and its funds have invested in more than 250 companies and currently manages funds to the value of EUR 340 m. The five investing funds currently managed by Bayern Kapital are Seedfonds Bayern, Clusterfonds Start-Up!, Innovationsfonds, Innovationsfonds EFRE and Wachstumsfonds Bayern.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A
- Geography: Germany, United States, Finland
Investor stats
- Total investments: 245
- Round size: Seed $1.1M–$5.9M; Series A $3.9M–$32M
- Lead/follow: 14% lead, 86% follow
- Last fund: May invest from a new fund soon — raised $26M in 2010
Portfolio highlights
- iATROS — As the population ages, the number of cardiovascular patients is steadily increasing. Every fourth German suffers from widespread diseases such as high blood pressure, atrial fibrillation, heart failure or coronary heart disease. We want to sustainably improve the lives of chronic and acute cardiovascular patients and contribute to reducing thetotal costs of over 60 billion euros annually.Our holistic approach allows healthcare providers to utilize the full power of smart health trackers in patient care. Combining the permanently gathered vital data with advanced AI analytics and medical expertise substantially increases the treatment outcomes and thereby saves lifes. We believe every patient deserves the convenience to have 24/7 doctor access and feel safe.
- Delicious Data — Delicious Data offer a demand forecast engine to solve the problem of planning uncertainty in the food service and catering industry. Delicious Data machine learning solution enables kitchen chefs to optimize purchase and production planning saving valuable resources and reducing costs.
- Samdock — SaaS sales solution for SMBs in Europe. CRM is too expensive. Too tedious. Too slow. Too rigid. Too complicated. Too boring. This is what we hear every day. Thats why we built Samdock. Our passion is to help SMBs grow and make sure that Sales can be simple and fun! Our aim is to be the leading AI driven sales automation for SMBs
MIG Capital is one of the leading German VC Investors. We invest in European Deep Tech and Life Sciences from early to late stage (Seed, Series A, and beyond). We use investments to shape a better tomorrow, today. Our team currently manages 17 MIG public venture capital funds regulated by BaFin, the German financial markets authority. These fundsoperate with more than EUR 1.2 billion capital committed by >60,000 private investors across Germany and Austria.Today, our portfolio consists of 30 companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: Germany, France, Austria
Investor stats
- Total investments: 96
- Round size: Series A $2.2M–$40M; Series B $1.6M–$54M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — raised $70M in 2014
Portfolio highlights
- NcodiN — The High Performance Computing (HPC) and ArtificiaI Intelligence (AI) era requires unprecedented computing capabilities. With this in view, industry is heading towards zettascale supercomputers, based on >100k processing units. Chiplets-based disaggregated processors and memory-centric computing architectures are taking over and require an ever more intensive communication between dies. Thus, today interconnect bottleneck is the main
- GlassPoint Solar — GlassPoint provides solar steam generators to the oil and gas industry for applications such as Enhanced Oil Recovery. It replaces gas-fired steam generation with solar, GlassPoint can reduce EOR gas consumption by up to 80 percent. The company was founded in 2008 and headquartered in Fremont, California.
- Zadient Technologies — Zadient produces semiconductor manufacturing materials that are critical for the entire silicon carbide (SiC) value chain
KfW gives impetus to economic, social and ecological development worldwide. As a promotional bank under the ownership of the Federal Republic and the Länder (federal states), it offers support to encourage sustainable improvement in economic, social, ecological living and business conditions, among others in the areas of small and medium-sizedenterprise, entrepreneurialship, environmental protection, housing, infrastructure, education finance, project and export finance, and development cooperation.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series A, Series B
- Geography: Germany, India, United Kingdom
Investor stats
- Total investments: 158
- Round size: Series A $2.2M–$7.7M; Series B $3.3M–$17M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Andercore — Andercore connects global suppliers and local buyers on one AI-driven platform, automating inventory selection, pricing, quotes, financing and global distribution at scale.
- AtlasEdge — AtlasEdge is an edge data center business with a mission to create the leading-edge platform, delivering seamless, localized and ultra-low latency digital infrastructure to customers. They provide a wide range of direct connectivity options to enable connectivity within their datacenters. All cabling is installed and managed by AtlasEdge and itsengineering team to ensure speed of installation and guaranteed quality and management.
- Quantum Systems — Our vision is to become the global leader in providing aerial data for decision making by the use of our drones.
NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.
Show more...Investment focus
- Industry: Information Technology, Software, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Germany, United States, France
Investor stats
- Total investments: 131
- Round size: Seed $219k–$7.7M; Series A $3.8M–$33M; Series B $3.8M–$71M
- Lead/follow: 21% lead, 79% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- ENTRYZERO — ENTRYZERO is a cybersecurity startup that develops an AI-powered software platform specializing in Threat Exposure Management,the company helps organizations continuously monitor their digital attack surface from a hacker’s perspective to identify and mitigatevulnerabilities automatically.
- OMMM — OMMM Operations Management Solutions is a software house that specializes in the digitization and automation of industrial planning.
- Emergence Therapeutics — Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as anADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration. Emergence is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Germany, United States, United Kingdom
Investor stats
- Total investments: 196
- Round size: Series A $3.1M–$33M; Series B $7.7M–$55M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $222M in 2019
Portfolio highlights
- nyra health — myReha is an artificial intelligence and evidence-based neurological research tablet app that offers a revolutionary form of therapy. myReha was founded in 2020 and was headquartered in Vienna, Austria.
- Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
- Beren Therapeutics — Beren Therapeutics is a biotechnology company that develops innovative therapies to make them accessible to every patient. The company was founded in 2020 and is based in Thousand Oaks, CA.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 87
- Round size: Series A $5.5M–$31M; Series B $4.9M–$83M; Series C $5.8M–$48M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $113M in 2018
Portfolio highlights
- T-CURX — T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designedto improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care.
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
b.value AG are into Biotechnology investments.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Chemical
- Stage:Seed, Series A
- Geography: Germany, Poland
Investor stats
- Total investments: 14
- Round size: Seed $478k–$2.5M; Series A $3M–$39M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- PL BioScience — STEM CELL EXPANSION IN SAFE AND REPRODUCIBLE CONDITIONS. We deliver advanced 2D and 3D cell culture solutions based on human Platelet Lysate – for basic research, cellular therapeutics and clinical applications. Choose between different safety grades meeting your needs: Research Grade, GMP Grade or GMP-Clinical Grade.
- Cultimate Foods — At Cultimate, we are transforming the flavor and aroma industry with natural innovative ingredients.
- traceless materials — traceless materials offer a holistically sustainable alternative to plastics: 100% biobased on plant residues, compostable under natural conditions, and free of toxic chemicals. For a future free of pollution and waste!
TGFS - Technologiegruenderfonds Sachsen is an early stage VC fund targeting high tech startups with strong growth potential. The fund invests into ventures located in Saxony/Germany, Europe's leading semiconductor cluster. The team has invested into more than 120 companies so far, including more than 40 investments from the currentfund.
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Seed, Series A
- Geography: Germany, United States
Investor stats
- Total investments: 154
- Round size: Seed $932k–$6M; Series A $1.9M–$15M
- Lead/follow: 22% lead, 78% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Cyber Insight — Cyber Insight - Measure, Manage, Mitigate Cyber Risks
- Fusion Bionic — Fusion Bionic is a solution provider for laser-based surface functionalization
- HandsOn Robotics —
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.
Show more...Investment focus
- Industry: Software, SaaS, Artificial Intelligence
- Stage:Seed, Grant
- Geography: Germany, United States
Investor stats
- Total investments: 87
- Round size: Seed $365k–$3M; Grant $80k–$165k
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- mo:re GmbH — We offer standardized tissue cultures and protocols to better predict drug responses and investigate disease models.
- Atrya — Atrya develops regulatory-compliant blockchain payments for international companies.
- DEALCIRCLE — DealCircle is a digital M&A solution and partner of hundreds of M&A advisors. We support in identifying buyers and addressing the market. This provides investors access to a comprehensive deal flow of relevant projects.
Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 99
- Round size: Series A $4.7M–$22M; Series B $5.2M–$44M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Streaming21 — Streaming21 is a solution provider of seamless on-demand and IP broadcasting service platform for connected digital home.
- Helomics — Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
- Precision Therapeutics — Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients.
eCAPITAL is a venture capital investor that provides early to growth stage funding to technology and deep tech companies.
Show more...Investment focus
- Industry: Information Technology, Software, Manufacturing
- Stage:Series A, Series B
- Geography: Germany, United States, Italy
Investor stats
- Total investments: 120
- Round size: Series A $2.7M–$14M; Series B $3.1M–$35M
- Lead/follow: 70% lead, 30% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Cleafy — A new era for online fraud management: Cleafy combines in real-time all the most advanced fraud detection technologies in one fraud management solution.
- VisioLab — Instantly scan products for self-checkout, using the iPad camera - no barcodes needed. Designed for speed, simplicity and human centricity.
- QuoIntelligence — Our finished intelligence will significantly reduce your operational risks and allow you to make informed security decisions.
bmp Ventures is an innovative Venture Capital Company from Berlin. Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Seed, Series A
- Geography: Germany, United States, Austria
Investor stats
- Total investments: 120
- Round size: Seed $165k–$3.4M; Series A $30k–$5.9M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Sedivention — Fight obesity within 20 minutes - fast, effective, long-term. A new weight-loss therapy for the treatment of obesity. Just a view minutes will change your life.
- Solar Materials — SOLAR MATERIALS developed a recycling technology for solar modules, which recovers all raw materials for a circular solar industry.
- Litherm Technologies — Litherm Technologies GmbH is a German deep‑tech startup focused on decarbonizing lime and cement production using fully electric kiln technology.
bm|t supports innovative and growth-oriented companies in Thuringia with equity investments and venture capital.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A
- Geography: Germany, United States
Investor stats
- Total investments: 69
- Round size: Seed $461k–$7M; Series A $1.1M–$9.4M
- Lead/follow: 59% lead, 41% follow
Portfolio highlights
- Altavo — Altavo operates as a medical device startup. Altavo harness the power of machine learning and state-of-the-art sensor technology to improve the lives of people who have lost their voice.
- Peeriot — Peeriot is a B2B software high-tech startup with a breakthrough in IoT. Peeriot offers a low-code software suite that simplifies IoT data sharing by tenfold.
- Influnate — Influnate is a tool that allows you to send and receive money via social media. Influnate enables users in social networks to “send and receive money easily, securely and quickly”. This can be done with a comment, a link, or via the Influnate web application. “Redirects to paid websites are a thing of the past,” said the startup.
Pre-Seed to Series A for Berlin-based founders. Where 30 years of expertise, capital and execution power meet.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Seed, Series A
- Geography: Germany, United States, United Kingdom
Investor stats
- Total investments: 226
- Round size: Seed $1M–$5.5M; Series A $2.2M–$10M
- Lead/follow: 19% lead, 81% follow
- Last fund: Likely still investing — raised $33M in 2022
Portfolio highlights
- dentolo — dentolo operates a dental insurance and ecosystem centered around customer needs.With its insurance solution, the company covers 100% in dental, instantly, with best value-for-money, market-leading customer satisfaction and an unmatched modern retail experience within its ecosystem. It addresses consumer demand with dental professionals in 25+regions, reaching 40m+ people nationwide. The company owns proprietary and scalable acquisition channels with the #1 dental guide in DACH and a deeply integrated ecosystem. It relentlessly focuses on customer experience and products that solve real-world pains to make dental care more transparent, affordable, and human.
- Famedly — Der Messenger der Gesundheitsbranche, der auch medizinische Arbeitsprozesse abbildet.
- dsb Deutsche Sanierungsberatung — dsb Deutsche Sanierungsberatung provides easy and sustainable solutions for climate-friendly homes energy-efficient renovations for homeowners.
Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.
Show more...Investment focus
- Industry: Software, SaaS, FinTech
- Stage:Series A, Seed, Series B
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 97
- Lead/follow: no public data
Portfolio highlights
- Finoa — Finoa is the leading European crypto-asset management platform, empowering businesses and institutions to engage with crypto safely and intuitively.
- Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
EQT Ventures is a European VC fund with just over €2.3 billion in total capital raised. EQT Ventures I launched in May 2016, with commitments totaling €566 million and a simple mission - to be the kind of VC the team would have liked to have had on their own startup journeys. Recognizing that building and growing a company takes more than justcapital, the EQT Ventures team provides founders with support and advice throughout different stages of growth. EQT Ventures doesn't focus on particular markets or industries, but on bold and ambitious founders who have the grit and determination to build global success stories. EQT Ventures II launched in November 2019, with commitments totaling €660 million. EQT Ventures III launched in 2022, with commitments totaling €1.1 billion, making it the biggest European Venture Capital fund committed to early-stage tech startups. The EQT Ventures team is based across six offices in London, Stockholm, Berlin, Paris, Amsterdam, Paris, and San Francisco, taking a locals-with-locals approach and supporting founders on the ground. Motherbrain, EQT Ventures' in-house-developed artificial intelligence (AI) platform, ensures the team has a data-driven approach and has driven more than $100 million in portfolio company investments.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Seed, Series B
- Geography: Sweden, Germany, United States
Investor stats
- Total investments: 255
- Round size: Seed $3.3M–$14M; Series A $6.4M–$44M; Series B $15M–$100M
- Lead/follow: 56% lead, 44% follow
- Last fund: Likely still investing — raised $1.1B in 2022
Portfolio highlights
- Wolt — Wolt delivers from the best restaurants and stores around you.
- Siilo — Doctolib Connect is a secure medical messenger platform designed for healthcare professionals. Communicate patient data with teams and colleagues.
- Holidu — Holidu is one of the fastest-growing travel tech companies worldwide that aims to finally make the search and booking of vacation rentals easy. Its search engine uses proprietary image recognition technology to compare the prices of millions of rental properties across hundred of websites including Airbnb, Booking.com, and Homeaway. This enablesusers to quickly find the ideal accommodation and to save up to 55% on their bookings. It was founded in 2014 by brothers Johannes and Michael Siebers and is headquartered in Munich, Bayern, Germany.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 200
- Round size: Series A $19M–$176M; Series B $16M–$155M; Series C $19M–$113M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Inflazome — Situs gacor premium Megawin188 paling banyak di minati oleh semua kalangan karena pecah selayar tanpa henti dan memiliki tampilan yang sangat memanjakan mata.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Germany, Austria, Ireland
Investor stats
- Total investments: 11
- Round size: Series A $3.9M–$15M; Series B $20M–$70M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
- Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Innovative post-revenue startups with first customers trust us as highly reliable investors. We have been an active player in the venture capital market for over 25 years. Due to our evergreen approach, we offer institutional venture capital without the limitations of the usual fund structure. Predominantly we invest straight equity. Additionally,we can offer venture debt to mature startups close to break-even in order to avoid further dilution for founders. Being a private investment company we act as both lead investor or co-investor. We can also fulfill the private lead investor role for public investors like Bayern Kapital. Together we are increasing YOUR company's value.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Series A, Series B
- Geography: Germany, Italy, United States
Investor stats
- Total investments: 117
- Round size: Series A $428k–$6.6M; Series B $732k–$21M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- socialhub — Boost your social media success with SocialHub. Manage channels, schedule posts & get meaningful analytics. Try it out now!
- TalentRocket — Talent Rocket is a job search engine that enables its users to find jobs with a suitable work environment for them. Job seekers can select their preferred company culture, follow their favorite companies, and start career conversations with employers. Talent Rocket was founded in 2014 and is based in London, United Kingdom.
- Goodly Innovations — Goodly Innovations is the leading regulated industry-focused global Pharma 4.0 provider for extended reality shop floor guidance. From cleanrooms to secondary packaging areas, labs and more, Goodly can help improve Pharma and BioPharma clients efficiency, OEE, quality, training and more
With a track record of over 20 years in venture capital and experience from more than 200 investments in numerous companies BFB Brandenburg Kapital GmbH (BFB) is the most active equity investor in Brandenburg. BFB invests in fast-growing technology-orientated companies throughout the whole life-cycle. Target sectors are ICT/Digital Economy,Life Science, MedTech, Proptech, Industrial Applications. BFB invests in companies based in or with facilities in Brandenburg. The current VC fund is financed by the European Regional Development Fund (ERDF) an Investitionsbank des Landes Brandenburg (ILB).
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: Germany, United Kingdom
Investor stats
- Total investments: 74
- Round size: Seed $823k–$6.1M; Series A $2.7M–$13M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- Kupando — Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
- k2-mobility — Operators of heavy vehicle fleets are facing one of the most significant transformational challenges by switching to electric vehicles. The additional time for battery charging, the limited vehicle range as well as diligent planning of energy consumption need to be dynamically integrated and accounted for in their daily operations. K2Mobility's software PANION has a real-time connection to the transport and tour plans, to the vehicles, the chargers and the grid and is planning and optimizing charging for operational excellence, energy cost and Total Cost of Ownership.
- Captain T Cell — Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients. The company identifies novel high-efficiency TCRs for the development of T cell immunotherapies. It focuses on CMC- and preclinical development for their lead candidates.
Seed Fonds has a strong competence network with national and international investors, business angels & expertes from the industry. They are specialized in the development of comprehensive financing models offering stability and development opportunities on the long term.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Germany
Investor stats
- Total investments: 8
- Round size: Series A $2.2M–$6M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- miacosa — miacosa.de is operated by the Endorsed Goods GmbH. miacosa.de is a social shopping concept from Germany based in Cologne. Social Shopping the miacosa way means that members select their personal shopping team of experts and celebrities that present products they love on miacosa.de Miacosa is for members only. The free service starts with productsfrom the fields of Health Style, Home & Living, Kitchen and fashion accessories.
- Hemovent — Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.
- aquila biolabs — aquila biolabs is a German technology company focusing on the development of innovative laboratory devices for the analysis of shake-flask fermentations in biotechnological, chemical and pharmaceutical research and development.
start-ups, SMEs, technology, co-investment
Show more...Investment focus
- Industry: Biotechnology, Health Care, Information Technology
- Stage:Pre-Seed, Seed
- Geography: Germany, The Netherlands, Austria
Investor stats
- Total investments: 22
- Lead/follow: no public data
Portfolio highlights
- Filuta AI — Operationalized Composite Artificial Intelligence
- Resistell AG — Resistell is a antibiotic resistance test.
- iThera Medical — Explore optoacoustic imaging technology for non-invasive in vivo visualization and quantification of disease-related tissue biomarkers.
Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Private Equity
- Geography: France, United States, Germany
Investor stats
- Total investments: 180
- Round size: Series B $14M–$85M; Private Equity $110M–$247M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $466M in 2022
Portfolio highlights
- Senstronic — Senstronic designs and manufactures industrial sensing solutions focused on performance, reliability and technical expertise for demanding applications.
- Inventiva Pharma — Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library ofproprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
- Rivermark Medical — Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function. Developed by urologists to reliably reduce BPH symptoms with minimal side effects.
The German Federal Ministry of Research, Technology and Space (BMFTR) funds research programs, promotes in the fields of cutting-edge research, future technologies, innovation and space.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Grant, Seed, Series B
- Geography: Germany, United States, Canada
Investor stats
- Total investments: 63
- Round size: Seed $340k–$4.2M; Grant $294k–$11M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- ChemInnovation — Molecules from Spectra - For a World without UnknownsAs ChemInnovation, we work on innovative & tailored AI-solutions for analytical chemistry. Within our first years as a company, we were able to bring our intelligent software METIS to researchers and partners within renowned chemical companies. Our smart software METIS accelerates theresearch and development of our customers. Therefore, it empowers them to accelerate their research, understand their chemistry and make their products safer. To achieve this, we have developed our own chemically inspired AI models and smart algorithms, which we now use to automatically evaluate complex data. We combine know-how from the chemical and computer science worlds thereby translating results from academia into productive cloud-software.
- Circus Group — At Circus, we believe cooking should be a loved hobby but not a daily necessity. Driven by the mission to fuel people's busy every day we are building a radically more convenient, sustainable, and affordable solution in food delivery. Circus was established in 2021 in Hamburg, Germany.
- Rock Tech Lithium — Rock Tech Lithium Inc. is a mineral exploration company focused on the lithium industry. Based in Vancouver and listed on the TSX Venture Exchange and the Frankfurt Stock Exchange, the Company’s international board of directors provides a truly global presence and offers unique access to capital and projects.The Company holds an interest in theGeorgia Lake lithium project in the Thunder Bay Mining District of Ontario. The Georgia Lake project consists of approximately 80 leases and approximately 20 claims covering approximately 4,590hectares. The project is located in an area underlain by metasediments and metavolcanics of Archaen age. The Georgia Lake pegmatites contain lithium-bearing spodumene. The spodumene-bearing pegmatites of the Georgia Lake area are located approximately 140 kilometers northeast of the city of Thunder Bay.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 26
- Round size: Series A $5.3M–$176M; Series B $5.3M–$45M; Series C $8M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $1.2B in 2022
Portfolio highlights
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
- HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.
BlueYard backs founders building the interconnected elements that can become the fabric of our future.
Show more...Investment focus
- Industry: Software, Biotechnology, Internet
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 109
- Round size: Seed $1.2M–$14M; Pre-Seed $200k–$5.4M; Series A $7M–$47M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $185M in 2022
Portfolio highlights
- ETHGas — ETHGas aims to redefine how users engage with Ethereum by providing low-latency, 3ms settlement times, and real-time trading, as well as a comprehensive product suite for exact order execution.
- Cryptio — We offer enterprise-grade accounting, reporting, and audit software for your digital assets.
- Rapidata — Fast and reliable data labeling that powers your AI. Define your label needs now and get the results in minutes.
At better ventures we invest in early-stage founders who aim to change our world for the better.
Show more...Investment focus
- Industry: Software, Food and Beverage, E-Commerce
- Stage:Pre-Seed, Seed, Series A
- Geography: Germany, Switzerland
Investor stats
- Total investments: 50
- Round size: Seed $1.1M–$6.9M; Pre-Seed $1.1M–$3.3M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Enzo — Enzo is a Heidelberg based InsurTech startup offering modern and smart insurance coverage for homeowners. Instead of just reacting to claims, Enzo takes a proactive customer-focused approach to prevent damages from happening at all. Thus, Enzo is leading a paradigm shift in a €100+ billion market that has barely improved customer experience forover 100 years. Our Goal is to become Europe's smartest homeowners insurance.
- Primogene —
- Tokura — Tokura focused on redesigning outpatient surgery (Ambulantes Operieren) through an integrated system of specialised facilities, experienced teams, and automated technology.
Investing in the Future of Protein.We invest in visionary founders creating the future of food and materials.
Show more...Investment focus
- Industry: Food and Beverage, Biotechnology, Food Processing
- Stage:Seed, Series A, Series B
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 59
- Round size: Seed $1.3M–$7.5M; Series A $6M–$46M; Series B $15M–$226M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Shiru — Discover Shiru. We are an Ingredient Company that Identifies and Creates Functional Ingredients for the Plant-Based Industry.
- Xias Bio — Xias Bio is a biotechnology startup specializing in the production of recombinant proteins, offering formulators advanced soluble, active ingredients with improved attributes such as enhanced gel and film formation, as well as antioxidant properties. The company creates non-immunogenic natural motifs to produce a better delivery platform offunctionalities for research, beauty, and healthcare.
- Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!We have been investing at the frontier of technology and science for over 30 years. We know what it takes to succeed.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 93
- Round size: Series A $2M–$12M; Series B $5.1M–$20M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $94M in 2016
Portfolio highlights
- AYOXXA — AYOXXA is a biotech company commercializing innovative technology developed at the National University of Singapore (NUS). AYOXXA’s patented technology platform is producing a new generation of biochips – merging biology with IT. This allows the biochip to accumulate large numbers of applications – measuring multiple protein markers for cancer,allergies, cardiovascular and infectious diseases – in a single test.
- SIRION BIOTECH — Viral Vector Technology as key enabler for innovative therapeutics. Viral vectors are a tool commonly used by molecular biologists to deliver genetic material into cells. This technique enables research of gene function and innovative therapeutics designed to correct defective genes and cancer. These technologies also assist in the discovery ofnew drug, food and cosmetic compounds. SIRION is a global leader in viral vector technology for gene modification of mammalian cells. Along with custom services, the company stands ready to outlicense its unique technologies. An initial target currently being pursued by one of SIRION's partners is a gene therapeutic for cervical cancer. The company started business in 2007 and since then has been changing the paradigm of viral vector supplies. Specifically, all commonly applied vector types are now available within a matter of weeks - adenovirus, adeno-associated virus (AAV) and lentivirus - and a full range of virus related services is at your fingertips spanning from particle production to virus driven cell modelling, all at highest titers and in quantities required for preclinical, clinical and animal testing.The company is easily accessible with presence in Munich, Tokyo, New Hampshire and Tel Aviv. Commercial arrangements range from fee-for-service over exclusive rights on single clones all the way to milestone & licensing arrangements. The business model proves successful: an annual 70% growth since 2007 and experienced in more than 500 projects for both the academic and industry sector.The company is privately held and has over the years raised funds from 8 investors both private and government. In order to support further growth and to benefit from technology development in this exciting industry, the company welcomes new investors. Please contact Management for further information about the company and its future plans.
- CryoTherapeutics — CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries.
Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.
Show more...Investment focus
- Industry: Internet, E-Commerce, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: Germany, United States, Switzerland
Investor stats
- Total investments: 83
- Round size: Seed $1.1M–$8M; Series A $1.1M–$53M; Series B $4M–$59M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Q.ANT — Q.ANT develops photonic processors for AI and high-performance computing, utilizing light for information processing. The company also produces quantum sensors offering ultra-high magnetic field sensitivity in a compact form factor. These products aim to enable more intelligent and sustainable systems across various sectors like data centers,aerospace, and medical technology.
- XO Life — XO Life is to build the largest real-world evidence platform for patient insights for all medications and therapies. Together with one of Europe's leading research institutes for patient-centered research, the PROMIS Institute Germany of the Charité, and various pharmaceutical manufacturers, patient experiences are to be recorded in astandardized and systematic manner across a wide range of diseases. Patients are to be enabled to record their therapy course and outcome independently as well as scientifically validated so that these patient insights from real treatment practice can be used in the life science industry and by medical professions.
- Patronus Group — Rethinking elderly healthcare
Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 45
- Round size: Seed $2.4M–$15M; Pre-Seed $125k–$7.8M; Series A $12M–$37M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Calibre — Calibre uses causal AI in conjunction with clinical expertise to help people understand what is truly influencing their health and how to modify it.
- Modern Relay — Modern Relay provides context graph for enterprise AI.
- Theorema — Autonomous R&D agents for biotech, pharma, chemicals, and materials. Theorema analyzes data, recovers R&D costs, and accelerates discovery. #1 on BixBench.
Investing early in Europe's most passionate founders.
Show more...Investment focus
- Industry: Health Care, Software, Financial Services
- Stage:Seed, Series A
- Geography: Germany, Austria, United Kingdom
Investor stats
- Total investments: 79
- Round size: Seed $1.2M–$7.7M; Series A $3.8M–$31M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- a2zebra — a2zebra is a zebra company that specializes in instructional technology for elementary school kids.
- Dermanostic — Dermanostic is an e-health app where patients receive a medical diagnosis and therapy recommendation for skin diseases.
- microsynetics GmbH — Developing hardware and software to help elderly people gaining more freedom and quality of life. Our first product is an emergency wristband which works together with an app, also connecting relatives via smartphone and phone integrated in the emergency wristband. The automated AI-based fall detection guarantees help even when the user - afteraccident - isn't capable anymore of activating the emergency call via integrated button.
S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.
Show more...Investment focus
- Industry: Biotechnology, Guides, Genetics
- Stage:Series B, Series A
- Geography: Germany
Investor stats
- Total investments: 9
- Round size: Series B $3.6M–$9M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Innolume — Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power.
- Protagen — Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
- Scienion — SCIENION AG is a life science company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. They provide their customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomicsand proteomics fields – from early research to manufacturing.
Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Germany, United States, France
Investor stats
- Total investments: 36
- Round size: Seed $1.1M–$8.7M; Series A $3.6M–$28M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Robeaute — Redesigning the future of neurosurgery by creating the new standard device that will provide surgeons with seamless access to delicate areas of the brain parenchyma and with real-time data.
- Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
- Sphingotec GmbH — Improving patient outcomes with innovative diagnostics for critical care: Actionable insights in real-time
ERP Startfonds KfW finances and supports, among other things, business start-ups, small and medium-sized enterprises.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Apps
- Stage:Series B, Series A
- Geography: Germany, United States
Investor stats
- Total investments: 6
- Lead/follow: no public data
Portfolio highlights
- tolingo — tolingo is one of the most renowned and successful translation agencies in Germany – a fact which motivates us in our work across every division of our company every day and helps drive us to constantly improve the services we offer to our clients. A human touch is crucial, whether in terms of our employees’ respectful, open interaction with oneanother at our headquarters in Hamburg, our consultations and service meetings with our clients, or the close, productive working relationships we enjoy with our specialist translators and industry experts all over the world. We strive for collaborative success and partnerships on equal footing without losing sight of the expectations we’ve set for ourselves or the standards and goals we’re determined to meet. This is how we’ve been able to transform from a little translation agency into a globally present provider with a sophisticated portfolio of services – with market-leader status in our sights.
- Rodos BioTarget — Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents selectively into the center of the immune response - i.e., directly into antigen-presenting cells.RBT currently applies its TargoSphere® technology successfullyin various models of infectious diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis, Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient immunity caused by antigen-presenting cells - like chronic inflammations, cancers, allergies, and autoimmune diseases - may be addressed by RBT’s TargoSphere® technology.
- Intelligent Apps — In 2009 founders Niclaus Mewes and Sven Kuelper launched "mytaxi" - the first taxi app with a direct connection between passenger and driver. mytaxi has grown to the fastest growing taxi-app with more than 7 million downloads and 35.000 connected taxis. mytaxi is available in over 40 German cities as well as Washington, Madrid, Barcelona,Warsaw, Vienna, Graz, Salzburg and Zurich. Investors include T-Venture Holding GmbH (Deutsche Telekom AG), Daimler Mobility Services GmbH (Daimler AG), KfW, e42 GmbH and Lars Hinrichs (Cinco Capital GmbH).mytaxi brings a demand for quality to the taxi service for the first time. Every driver using mytaxi has the ability to become a contractor and build their own client base by consistently providing passengers with good service and earning high customer ratings. Through the given peer-to-peer connection between passenger and driver the whole ordering process becomes very transparent for both. The passenger can not only track the taxi’s arrival in the app but also see which driver is coming. For the driver the cost modell is very attractive as they only pay for a successfully completed trip.The aim of mytaxi is to drive the concept of urban mobility and to further strengthen its position as an international leader in this field. Accordingly to that mytaxi took over the app development services for Daimler Mobility Services GmbH (Daimler AG).
Delivery Hero - Always delivering an amazing experience.
Show more...Investment focus
- Industry: E-Commerce, Information Technology, Food Delivery
- Stage:Series A, Seed, Series B
- Geography: Singapore, Egypt, Brazil
Investor stats
- Total investments: 25
- Lead/follow: no public data
Portfolio highlights
- Charan — Charan is an operator of an e-commerce platform intended to sell second-hand fashion apparel.
- Qashier — Qashier provides smart point-of-sale solutions that help merchants digitize their businesses. Its flagship product is the Qashier Smart Terminal, a connected, multi-purpose device that combines a payments hub, powerful POS software, and a proprietary app store into one uniquely designed device. Qashier enables merchants to start, run, and growsuccessful stores with just one terminal on the counter. Qashier was founded in 2019 and is headquartered in Singapore.
- OneOrder — One Order delivers exceptional produce, custom cuts of meat, high-quality seafood, and imported foods offering an array of global flavors.
TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series C
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 102
- Round size: Series B $7.5M–$50M; Series C $10M–$55M
- Lead/follow: 19% lead, 81% follow
- Last fund: May invest from a new fund soon — raised $290M in 2005
Portfolio highlights
- Definiens — Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
- Lamab Biologics — Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.
- Rapid Micro Biosystems — Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Elevat3 Capital is the venture capital arm of serial entrepreneur and investor Christian Angermayer and his family office Apeiron Investment Group. With a focus on German-speaking countries, we partner with companies that meet our three-level criteria, then elevate them by providing more than just capital. We use our exceptional network, spanningindustry, politics, arts, science and technology, to give our portfolio companies access to high-profile leads and advisors, enabling them to grow rapidly and achieve amazing results.
Show more...Investment focus
- Industry: FinTech, Apps, Social
- Stage:Series A, Series B, Post-IPO Equity
- Geography: Germany, United Kingdom
Investor stats
- Total investments: 6
- Round size: Series A $45M–$157M
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- Formo — Formo is shaping the future of dairy with precision fermentation, creating animal-free recombinant milk proteins with exceptional functionality.
- Naga — NAGA is disrupting the worlds of trading and investment by making them more open and inclusive. It is the single solution that's got it all: Trade, Earn, Invest, Acquire, Connect, Pay; all in one seamless and unified ecosystem that is radically social! Traders and investors from all around the world can use the NAGA technology every day inmany powerful ways: invest in the financial markets (physical stocks, CFDs in stocks, indices, currencies, energies, metals, commodities and cryptocurrencies), make payments in fiat and cryptocurrency, learn about wealth as well as communicate and connect with like-minded people anywhere and anytime. NAGA expands the one-of-a-kind experience with many other unique and innovative services such as the NAGA Mastercard, the AI-driven Portfolio baskets, the world’s first messenger where traders can exchange ideas and opinions in its public channels, Auto-Copying other traders and copying trading signals thanks to the revolutionary NAGA Signals feature.NAGA is really greater than the sum of its parts and powerful when its full spectrum of products and features are used together.
- Legendairy Foods — Formo is shaping the future of dairy with precision fermentation, creating animal-free recombinant milk proteins with exceptional functionality.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Lowercarbon Capital backs kickass companies slashing CO2 emissions, sucking carbon out of the sky, and buying us time to unf**k the planet.
Show more...Investment focus
- Industry: Renewable Energy, Energy, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 207
- Round size: Seed $3.7M–$12M; Series A $10M–$50M; Series B $20M–$150M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $350M in 2022
Portfolio highlights
- Terraton — Terraton is a biochar platform that provides equipment, design, and financing to agribusiness operators.
- Isometric — Isometric is a carbon removal standard and registry.
- SolarSquare Energy — Visit Solarsquare, India's only UL-certified solar installation company for hassle-free commercial & residential solar panel installation at 0 cost EMI & PPA options.
Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.
Show more...Investment focus
- Industry: Medical, Therapeutics, Biotechnology
- Stage:Series A, Series B
- Geography: Germany
Investor stats
- Total investments: 8
- Round size: Series A $1M–$1.9M; Series B $1.6M–$2.9M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Siltectra — SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.
- Isarna Therapeutics — Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
Venture capital investment can raise funds for your small business. Venture Capital Firms in the UK like Agronomics is a biotech venture capital firm which invest into the clean meat sector.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Food Processing
- Stage:Series A, Seed, Series B
- Geography: United States, Finland, Germany
Investor stats
- Total investments: 46
- Round size: Seed $894k–$11M; Series A $6M–$47M; Series B $2.4M–$55M
- Lead/follow: 48% lead, 52% follow
Portfolio highlights
- Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
- SuperMeat — SuperMeat is an Israeli bio-tech and food-tech company, developing a technology to create clean meat from chicken cells in a safe and controlled environment, external to the animal’s body. SuperMeat is set to revolutionize the meat industry from its core, aspiring to secure a better future for humans and animals alike. Clean meat is grown in acontrolled, sterile environment without the use of antibiotics and without any possibility of fecal contamination, such as salmonella. Clean meat will require significantly less resources for its production (99% less land, 90% less water), making it both a healthy and sustainable food source for the coming century.
- Liberation Bioindustries — Liberation Labs believe that by innovating technology, It can free the world from the costs of industrialized agriculture and unlock a new era of accessible, healthy foods. The mission is to make precision fermentation by commercializing purpose-built manufacturing facilities for industrial biotech.
Gruenderfonds Ruhr is an investment firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Renewable Energy
- Stage:Series A, Seed, Series B
- Geography: Germany
Investor stats
- Total investments: 12
- Round size: Seed $9.1M–$10M; Series A $4.9M–$95M; Series B $16M–$35M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Cyberdesk — CyberDesk helps you to minimize data exposure while ensuring that the right identities get the right access at the right time.
- Factor2 Energy — Factor2 Energy builds CO₂-based geothermal power systems designed to deliver clean, scalable baseload energy without fracking, ultra-deep drilling, or water-intensive processes.
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, Spain
Investor stats
- Total investments: 138
- Round size: Seed $2.3M–$17M; Series A $3.8M–$95M; Series B $12M–$72M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- EvlaBio — EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical).
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- DAMAE Medical — Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis.
Collaboration with outstanding initiators with exceptional insights, from inception through all levels of progress. Lima Ventures supports visionary founders as well as provides certain services to early startups. We seek innovative technology-driven entrepreneurs who generate and lead companies that will inspire millions.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, FinTech
- Stage:Seed, Pre-Seed
- Geography: Turkey, United Kingdom, Estonia
Investor stats
- Total investments: 32
- Lead/follow: no public data
Portfolio highlights
- Shippn — International package forwarding service. Shop from Amazon, Shein, Macy's worldwide. Fast shipping with DHL & FedEx. Trusted by 50,000+ customers.
- heybooster — Heybooster is a provider of analytical tools to ecommerce companies to take better digital marketing decisions.
- Mars Studios — Mars Studios is an experienced team of growth hackers & marketers that can help you to increase your revenue. Rocket Your App to Success: Mars Studios
VF-Funds for innovative and scalable start-ups from the Rhineland Area, Germany
Show more...Investment focus
- Industry: Software, Health Care, Manufacturing
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, Spain
Investor stats
- Total investments: 27
- Lead/follow: no public data
Portfolio highlights
- IonKraft — IonKraft's barrier coating technology for plastic packaging, offers excellent product protection while being 100% recyclable.
- Eeden — Eeden engages in the manufacture and supply of textiles.
- Planted Green — Planted Green plants mixed forests to compensate for CO2 emissions.
We are the home for entrepreneurs with a big vision who want to create something less ordinary. Something that matters. For all of us.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A
- Geography: Germany, United Kingdom, Finland
Investor stats
- Total investments: 66
- Lead/follow: no public data
Portfolio highlights
- Elio — Putting leading scientific data into context, to enable others to respond to climate change’s dynamism and act on solutions with confidence.
- Ocean Ledger — Precision analytics to design, implement & monitor coastal mitigation and adaptation.
- NatureMetrics — NatureMetrics is the World-Leading provider of Biodiversity monitoring data, using eDNA surveys, metabarcoding & more. Book your demo today!
SFO is an entrepreneur from the start-up environment and medium-sized companies. SFO offers complementary expertise, reliable capital, and an effective network.
Show more...Investment focus
- Industry: Food and Beverage, B2C, Pet
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany
Investor stats
- Total investments: 6
- Lead/follow: no public data
Portfolio highlights
- Younikat — VEGDOG - vegan dog food is the first 100% vegetable and gluten-free complete feed for dogs, which was developed in a one-year development phase in cooperation with specialist veterinarians and specialist laboratories due to a feed allergy in our dog Nelson.
- ecoLocked — ecoLocked is your partner to create a climate-positive built environment. We develop CO2-optimized recipes for concrete based on carbon-negative biochar admixes. Our admixes allow to store captured CO2 in buildings, reduce direct emissions from concrete production, and provide multiple functional benefits, such as improved thermal insulation.
- ProteinDistillery — ProteinDistillery: The Future of Sustainable Protein Production. We transform industrial side-streams into functional protein ingredients.
96 Normal 0 false false false EN-GB X-NONE X-NONE
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Germany, Finland, The Netherlands
Investor stats
- Total investments: 11
- Lead/follow: no public data
Portfolio highlights
- Surgify — Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa).
- ATRO Medical — ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype.
- microDimensions — microDimensions provides digital pathology software and services: image analysis, 3D histology reconstruction, protein multiplexing, stereology, image registration.
Biotech Investor funding in Germany at a glance
Stats across 758 deals from 874 investors.
Access all 874 investors in Germany Biotech startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Germany investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 874 investors investing in Germany Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!